Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Hepatocellular Carcinoma Clinical Trial

Official title:

A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06034860
• Other study ID #: MT-8421-001
• Status: Recruiting
• Phase: Phase 1
• Start date: November 1, 2023
• Est. completion date: October 2026

Study information

• Verified date: April 2024
• Source: Molecular Templates, Inc.
• Contact: Kristina Dabovic
• Phone: 1862-204-7184
• Email: kristina.dabovic[@]mtem.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types. MT-8421 is an investigational drug that specifically targets and depletes cytotoxic T-lymphocytes-associated protein 4 (CTLA-4) expressing cells in an effort to directly dismantle the tumor microenvironment for the treatment of patients with advanced solid tumors.

Description:

This study is conducted in two parts. The study will enroll up to 200 total participants (up to 40 in Part A and up to 160 in Part B).

Part A (Dose Escalation) is designed to estimate the maximum tolerated dose (MTD) of MT-8421 as monotherapy and in combination with nivolumab.

Part B (Dose Expansion) is designed to identify the dose(s) to be studied in Phase 2.

The drug being tested in this study is called MT-8421. The study will evaluate safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-8421 as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types.

MT-8421 will be given as an intravenous (IV) infusion on Days 1, 8, 15, and 22 of a 28-day cycle. H1 and H2 blockers and anti-pyretics will be given to all patients as pre-medication prior to each dose in Cycle 1. Anti-pyretics will be required for 24 hours after the first dose in Cycle 1. Use of pre-medication will be at the discretion of the Investigator for subsequent doses.

In Parts A and B, a subject may participate for the following three (3) periods:

• Screening Period- up to 28 days before the first dose of MT-8421

• Treatment Period- active period where a subject will receive doses of MT-8421 over a 28-day treatment period.

• Follow-up Period- up to 24 months after the second short term follow up visit.

In both parts of the study, participants can receive MT-8421 until their cancer worsens, side effects prevent further study treatment, or until the participant leaves the study for other reasons decided by the participant, the study doctor, or the sponsor of the study. After the second short term follow up visit participants will have a check -up of their disease every 12 weeks for 24 months.

The overall duration of the study will vary for each participant because study treatment will continue until unacceptable toxicity, withdrawal of consent, death, termination of the study by the sponsor, or fulfilment of another discontinuation criterion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: October 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed, unresectable, locally advanced, or metastatic melanoma, HCC, NSCLC, RCC, MSI-H/dMMR malignancies, urothelial carcinoma, esophageal squamous cell carcinoma, mesothelioma, SCCHN, or cervical carcinoma not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion, the standard treatment would not be in the patient's best interest.

Part A only: Evaluable only or measurable disease according to RECIST v1.1 Part B only: At least 1 measurable tumor lesion according to RECIST v1.1

• Prior treatment must include a PD-1 or programmed cell death - ligand 1 (PD-L1) inhibitor. Prior treatment with a CTLA-4 inhibitor is not required.

• Eastern Cooperate Oncology Group (ECOG) performance score of 0 or 1

• Adequate bone marrow function, as determined by:

• Absolute neutrophil count (ANC) = 1500/ µL (should not have received growth factors within 2 weeks prior to screening)

• Platelet count = 75,000/ µL

• Hemoglobin = 8.0 g/dL (no red blood cell transfusion within 2 weeks of study treatment start is allowed)

• Adequate renal function, based on estimated creatinine clearance (eCrCl) = 50 mL/min, calculated by the Cockcroft-Gault equation.

• Adequate hepatic function, as determined by:

• Total bilirubin = 1.5x upper limit of normal (ULN) or = 2x ULN direct bilirubin for patients with Gilbert's Syndrome

• Aspartate transaminase (AST) = 3x ULN (or = 5x ULN if liver metastasis or HCC).

• Alanine transaminase (ALT) = 3x ULN (or = 5x ULN if liver metastasis or HCC).

• Adequate serum albumin (albumin = 2.5 g/dL)

• Availability of a lesion that can be biopsied with acceptable risk.

• Patients capable of bearing children must have a negative highly sensitive pregnancy test within 72 hours before the start of treatment. Patients who are postmenopausal (> 1 year since last menstrual cycle) or permanently sterilized (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy) may be considered as not of reproductive potential.

• Patients of reproductive potential must agree either to abstain continuously from heterosexual intercourse or to use a highly effective birth control method from signing the informed consent form (ICF) until 30 days after the last dose of MT-8421 and/or 5 months after the last dose of nivolumab for patients capable of bearing children and until 90 days after the last dose of MT-8421 for patients capable of fathering a child. Patients must not donate sperm during the study and for 90 days after the last dose of nivolumab or MT-8421.

Exclusion Criteria:

• Unwilling or unable to undergo 2 sets of 3 to 6 core tumor biopsies: one set at study baseline (prior to first dose of study drug) and one set between Weeks 6 through 8. A final optional set will be collected time of disease progression.

• Received approved or investigational treatment for the disease under study (except ipilimumab) where Exclusion Criterion 4 applies, requiring a washout that will be dependent upon prior ipilimumab dose and planned MT-8421 dose) within 4 weeks before the start of treatment. For small molecules [Molecular Weight (MW) < 0.9 kDa], the washout is 5 half-lives, but at least 2 weeks.

• Received tremelimumab within 30 days or ipilimumab 3 mg/kg within 60 days or ipilimumab 1 mg/kg within 30 days before the start of treatment. Once dose cohort of 32 µg/kg MT-8421 has been completed in dose escalation, a 30-day washout of ipilimumab is acceptable irrespective of prior dose.

• Any concurrent cancer treatment, apart from local treatment of non-target lesions for palliative intent (e.g., local surgery or radiotherapy). Patient must have recovered from the effects of the local treatment and be discussed with the medical monitor.

• History or current evidence of another neoplastic disease, except cervical carcinoma in situ; superficial non-invasive bladder tumors, curatively treated; Stage I to II non-melanoma skin cancer; prostate cancer managed by active surveillance; or any previous cancer curatively treated < 2 years before the start of treatment.

• Active autoimmune disease that required systemic treatment in the past. Patients who have not required systemic treatment for at least 2 years may be enrolled if permission is provided after discussion with the Medical Monitor (replacement therapy, e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed)

• Evidence of active, non-infectious = Grade 2 pneumonitis or current evidence of = Grade 3 other underlying pulmonary disease.

• Ongoing > Grade 1 immune-related toxicity caused by prior CPI therapy (i.e., PD-1 inhibitors, PDL1 inhibitors, or CTLA-4 inhibitors). Patients with stable endocrinological AEs (e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus) must have been on a stable dose of supplemental therapy for at least 2 weeks before screening to be eligible for this study. History of repeat Grade 2 pneumonitis or myocarditis on previous CPI and/or Grade 3 irAE on previous CPI treatment.

• Current evidence of new or growing central nervous system (CNS) metastases during screening. Patients with known CNS metastases will be eligible if they meet all the following criteria:

• Received radiotherapy or another appropriate therapy for the CNS metastases, if clinically Indicated

• Have stable CNS disease on the computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the ICF compared with prior neuroimaging.

• History or current evidence of significant cardiovascular disease before the start of treatment.

• Current evidence of active, uncontrolled hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV) (evidenced by detectable viral load by polymerase chain reaction) or acquired immunodeficiency syndrome (AIDS)-related illness.

• Serology and virology measurements are not required to be performed at screening, but any previously reported results should be used for eligibility purposes. Investigators will test per their discretion

• Patients with a history of treated hepatitis C and non-quantifiable hepatitis C virus- ribonucleic acid (RNA) may be enrolled.

• Patients on treatment for hepatitis B, hepatitis C, and/or HIV will be eligible if they have undetectable viral load (patients with HIV with CD4+ T-cell [CD4+] counts = 350 cells/µL may be enrolled).

• Patients with unintentional weight loss greater than 10% of their body weight over the preceding 2 months or less prior to first dose in the first cycle.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Carcinoma, Squamous Cell
• Cervical Cancer
• Esophageal Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Mesothelioma
• Microsatellite Instability
• Microsatellite Instability High
• Mismatch Repair Deficiency
• Non Small Cell Lung Cancer
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck
• Urothelial Carcinoma

Intervention

Drug:
• MT-8421
Experimental treatment with MT-8421
• Nivolumab
480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts

Locations

Country	Name	City	State
United States	NEXT Oncology	Fairfax	Virginia
United States	Horizon Oncology Research, LLC	Lafayette	Indiana
United States	The Angeles Clinic	Los Angeles	California
United States	Weill Cornell Medicine	New York	New York
United States	Washington University in St. Louis	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Molecular Templates, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Adverse Events	Evaluation of safety and tolerability of MT-8421 as measured by number of participants with Adverse Events, dose limiting toxicities (DLTs), abnormal physical exam findings, abnormal laboratory test results, abnormal radiographic findings, and/or patient reported symptoms	28 day cycle
Primary	To confirm the recommended Phase 2 dose (RP2D) of MT-8421 as monotherapy and in combination with nivolumab in patients with selected advanced solid tumor types.	Incidence of AEs	28 day cycle
Primary	Proportion of participants with objective response	Objective response rate (ORR) defined as the proportion of participants with either a complete response or a partial response as determined by investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	Up to two years (Part B)
Secondary	Objective response rate to assess preliminary efficacy	Objective response rate (ORR) defined as the proportion of participants with either a complete response or a partial response as determined by investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	Up to two years (Parts A)
Secondary	Duration of response to assess preliminary efficacy	Duration of response defined for participants with confirmed complete response or partial response as the time from the first documented tumor response to the date of radiographic progression progressive disease per RECIST v1.1	Up to two years (Parts A)
Secondary	Time to response to assess preliminary efficacy	Time to response defined as the time from the date of the first dose of the study treatment to the date of the first documentation of response (partial response or better) per RECIST v1.1	Up to two years (Parts A)
Secondary	Progression-free survival to assess preliminary efficacy	Progression free survival defined as the time from the start of treatment with MT-8421 to the date of radiographic progressive disease per RECIST v1.1 or death from any cause, not including clinical progression	Up to two years (Parts A)
Secondary	Disease control rate to assess preliminary efficacy	Disease control rate defined as proportion of patients who have achieved complete response, partial response and stable disease	Up to two years (Parts A)
Secondary	Characterize the pharmacokinetic (PK) profile of MT-8421 given as monotherapy and in combination with nivolumab in patients with selected advanced solid tumor types	Maximum observed plasma concentration (Cmax)	Up to two years (Parts A)
Secondary	Characterize the pharmacokinetic (PK) profile of MT-8421 given as monotherapy and in combination with nivolumab in patients with selected advanced solid tumor types	Half-life (t1/2)	Up to two years (Parts A and B)
Secondary	Characterize the pharmacokinetic (PK) profile of MT-8421 given as monotherapy and in combination with nivolumab in patients with selected advanced solid tumor types	Area under the concentration-time curve (AUC) from time zero to the last measurable concentration (AUC0-t), total exposure (AUC0-8)	Up to two years (Parts A and B)
Secondary	Characterize the pharmacokinetic (PK) profile of MT-8421 given as monotherapy and in combination with nivolumab in patients with selected advanced solid tumor types	Clearance (CL)	Up to two years (Parts A and B)
Secondary	Characterize the pharmacokinetic (PK) profile of MT-8421 given as monotherapy and in combination with nivolumab in patients with selected advanced solid tumor types	Volume of distribution at steady-state (Vss)	Up to two years (Parts A and B)
Secondary	Evaluate the immunogenicity of MT-8421 in patients with selected advanced solid tumors.	Anti-drug antibodies (ADA), Neutralizing antibodies (NAb)	Up to two years (Parts A and B)